A longevity startup backed by Brian Armstrong has raised $435 million in a series c funding round. The company, NewLimit, reportedly claims to have made a breakthrough in aging reversal and plans to use the funding for human trials. The startup's valuation has been reported to be $3.1 billion, although other valuations of related or similar companies have also been mentioned.